WebOut of six drugs under development HBV CpAM and AB-423 are in preclinical trials, AIC 649 and JNJ56136379 are currently in phase I development, Morphothiadin (GLS4) and NVR 3-778 is currently in phase II development. WebMorphothiadin is a potent inhibitor on the replication of both wild-type and adefovir …
GLS4 CAS:1092970-12-1 Probechem Biochemicals
WebGLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM), shows efficacy against ADV-resistant HBV mutations; strongly inhibits core gene expression (at 100 to 200 nM), suppresses virus accumulation in the supernantant of … WebMorphothiadin is a potent inhibitor on the replication of both wild-type and adefovir … integrity in leadership roles
GLS4 supplier - CAS 1092970-12-1 - EC-000.2493
WebAug 19, 2013 · In vitro, GLS4 was significantly less toxic for primary human hepatocytes … WebSingle- and multiple-ascending dosing showed that morphothiadin (GLS4) exposure increased in a greater than dose proportional manner over the single dose range of 2.5 to 240 mg. However, with the frequency and dosage of multiple dosing increasing, GLS4 showed autoinduction effect. Object: morphothiadin Anti-Infective Agents Antivirals WebMorphothiadin (GLS4) is a potent inhibitor on the replication of both wild-type and adefovir-resistant Hepatitis B virus (HBV) with an IC50 of 12 nM. Morphothiadin (GLS4), a nucleoside analogs that target the virus polymerase, can block the HBV replication cycle and HBV-associated chronic liver diseases. integrity in leadership examples